Cryo-Cell International Debt to Equity

Cryo-Cell International (CCEL) currently reports a debt-to-equity ratio of -1.04. That is below the Healthcare sector average of 0.34. Use the charts on this page to explore Cryo-Cell International's debt-to-equity ratio history and peer comparisons.

Cryo-Cell International's debt-to-equity ratio of -1.04 is lower than the Healthcare sector average of 0.34. That is roughly 404.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Cryo-Cell International's market price to a fundamental measure such as earnings, sales, or book value. At -1.04, CCEL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -1.04, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.34. From there, open related valuation or income-statement pages for Cryo-Cell International, and consider following CCEL for alerts when major investors trade the stock.

Cryo-Cell International is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -1.04 versus a sector average near 0.34. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CCEL with unrelated industries.